BioNTech develops a vaccine against Covid for children from 5 to 11 years that will present in weeks

Related news

The German laboratory BioNTech has developed a Covid vaccine for children between the ages of five and eleven. The aim of the pharmaceutical company is to present the results of the trial to the authorities around the world and request their approval, also in Europe, “In the next weeks”.

This has been pointed out by the medical director of the pharmaceutical company, Özlem Türeci, in statements to The mirror. “We are already preparing production“, has added.

It is the same vaccine as the one used for adults, “but with a lower dose and requires less filling,” Türeci specified.

In addition, the German biotech is testing a vaccine against Covid for children from six months. The results of this trial “will arrive at the end of the year”Said Ugur Sahin, CEO of the company.

At the moment, the European Medicines Agency is reviewing the data for the approval of the booster dose developed by Pfizer and BioNTech. Specifically, it is evaluating whether it is effective to administer this third dose six months after completing the immunization regimen in the general population.

It should be remembered that in Spain, the Ministry of Health and the autonomous communities have agreed to inoculate a booster vaccine only to some immunosuppressed patients. At least for now.

Leave a Comment